Key Highlights

  • Net loss was USD 297.1 million, or USD 1.99 per share, in the third quarter of 2026, compared with USD 212.8 million, or USD 1.56, a year earlier.
  • Research and development expenses rose 28.8% to USD 270.3 million, led by USD 130.9 million of product Manufacturing costs and USD 38.4 million of clinical trial costs.
  • Vaxcyte held USD 0.1 billion of cash and USD 2.1 billion of investments at September 30, 2026, before October offerings that included USD 575 million of convertible notes.
  • October 2026 topline results showed VAX-31 met all prespecified primary endpoints in the pivotal OPUS-1 adult Phase 3 trial of 3,572 adults aged 50 and older.

Wider Loss as Phase 3 and Manufacturing Spending Climb

Vaxcyte (NASDAQ:PCVX) filed its Quarterly Report for the period ended September 30, 2026 on November 4, 2026. As a clinical-stage company it reports no revenue, so the loss from operations of USD 308.3 million equals total operating expenses, up 27.2%. Net loss widened 39.6% to USD 297.1 million, with other income, net falling to USD 11.2 million from USD 29.6 million as foreign currency gains shrank by USD 12.0 million and interest income fell USD 6.1 million. General and administrative expenses rose 17.0% to USD 37.9 million on headcount and consulting costs. For the nine months, the net loss was USD 902.0 million, or USD 6.25 per share, against USD 520.1 million, or USD 3.83.

What the Spending Is Funding: VAX-31 and Launch Readiness

Manufacturing costs rose USD 20.2 million, which the filing ties to activity supporting potential future commercial launches. Clinical trial costs rose USD 18.7 million on the OPUS-1, OPUS-2 and OPUS-3 Phase 3 studies. Vaxcyte develops broad-spectrum pneumococcal conjugate vaccines using a cell-free protein synthesis platform. In OPUS-1, all 28 VAX-31 serotypes shared with Prevnar 20 or Capvaxive met noninferiority, though serotypes 3 and 12F missed the stricter threshold against Capvaxive and met only a historical threshold. Safety was similar to the comparators, and the FDA has granted Breakthrough Therapy Designation to VAX-31 in adults. OPUS-2 and OPUS-3 data are expected in the first half of 2027, as is the infant Phase 2 readout.

Funding Runway, Dilution and the Convertible Notes

The company said cash, equivalents and investments should fund operations for at least 12 months from the filing date, but it will need substantial additional Capital to complete development and commercialization. In February 2026 it sold 12,650,000 shares at USD 50.00 for net proceeds of USD 601.8 million, and in October it sold 8,584,375 shares at USD 64.00 plus USD 575 million of 1.50% convertible notes due 2032 with an initial conversion price of about USD 89.60. Shares outstanding rose to 149.3 million from 131.1 million at year-end. A USD 500 million at-the-market program remains unused. Non-cancelable manufacturing commitments total USD 524.4 million, and the accumulated Deficit is USD 3.1 billion, so spending is committed well ahead of any product revenue.

Where Things Stand

A larger research and manufacturing build, mainly. The loss bought Phase 3 execution and launch preparation, and VAX-31 met its primary endpoints in OPUS-1. Vaxcyte (NASDAQ:PCVX) still faces a widening loss, continued dilution and regulatory steps ahead, including a lot-to-lot consistency study before a Biologics License Application. Next markers are OPUS-2 and OPUS-3 data and the infant Phase 2 readout in the first half of 2027, plus how the October financing changes the cash position in the next report.